The head-to-head data boost expectations for Lilly's 'triple-G' drug as a major growth driver, though higher side-effect rates and discontinuations were reporte

The positive trial data mark the first major success for an individualized cancer vaccine and spur efforts to expand the approach.

The late-stage win supports Genmab's multibillion-dollar acquisition of Merus and lifts its shares.

The framework creates a 'plug and play' pathway for patient-specific therapies and draws praise from rare disease advocates.

The agencies are coordinating on policy to widen access to personalized treatments for rare diseases.

The deal hands Astellas rights to a Melbourne-developed cancer therapy it calls potentially best-in-class.

The closure is the third recent report of fatal events in autoimmune cell therapy trials, following Novartis and BMS.

The approval adds a new functional cure option for chronic hepatitis B.

The ruling found Novo failed to prove Lilly's superiority claims meaningfully harmed Wegovy sales.

The approval gives a new option for advanced pancreatic cancer patients who have already received treatment.

The combination moves toward possible approval in China for first-line lung cancer.

The policy reflects MAHA movement interest in peptides despite limited evidence for many wellness compounds.

The buyout gives Ferring rights to technology aimed at simplifying in vitro fertilization.

The survival benefit and priority review move the Merck therapy closer to approval.

The request questions whether the TrumpRx platform has saved Americans any money on prescription drugs.

The investigation found Epic selectively withholds patient data access, disadvantaging rival developers and drawing antitrust scrutiny.

The warning signals growing state pushback against drugmaker conditions on 340B discounted medicines.

The designation could grant seven years of US market exclusivity for the drug if approved.